The first-in-human trial of glycocalyx-edited autologous MSCs shows that engineering bone homing via sLeX expression reduces fragility fractures and increases bone density in advanced osteoporosis patients, with five-plus years of safety data and no serious adverse events.
The Cox et al. Phase 1/2a trial in Brain (2026) demonstrates that autologous adipose-derived MSCs reduce brain immune cell density and improve depression, fatigue, and pain in chronic TBI patients.
A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.
A 2026 meta-analysis pools 236 patients across 5 trials, and a 114-patient Phase 2 RCT shows MSC therapy achieves EASI-75 in 24% of severe AD patients. Exosome hydrogel delivery and batch consistency data now address the scalability questions that held this field back.
Multiple 2026 clinical trials and reviews show mesenchymal stem cell therapy is safe and feasible for Parkinson's disease — but what do the actual data say about efficacy, dosing, and what comes next?
A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.
Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
English 
Chinese 
Russian 
French